Wyoming Medicaid spending on GLP-1 drugs

How much did Wyoming Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $2.2 million for GLP-1 drugs paid through Wyoming Medicaid in 2025, across at least 2,315 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 76 rows of 140, so these figures are floors.

Pharmacies were reimbursed at least $1.6 million for GLP-1 drugs paid through Wyoming Medicaid in 2026 (quarter 1 only, as posted so far), across at least 1,556 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 9 rows of 38, so these figures are floors.

By year and ingredient

2020at least $33,330No data$377,472at least $64,590at least $155,061SuppressedNo dataat least $630,454
2021at least $75,850No data$648,794at least $86,697at least $44,400SuppressedNo dataat least $855,741
2022at least $211,653Suppressed$802,440at least $188,664at least $30,350SuppressedNo dataat least $1,233,107
2023at least $424,578at least $126,401$986,824at least $239,563at least $8,809SuppressedNo dataat least $1,786,175
2024at least $756,390at least $592,968at least $369,519at least $532,607SuppressedNo dataSuppressedat least $2,251,484
2025at least $571,466at least $757,142at least $40,525at least $875,830SuppressedNo dataNo dataat least $2,244,963
2026 (Q1)at least $462,048$669,494at least $34,550$455,716SuppressedNo dataNo dataat least $1,621,808

By product, 2025

Ozempicat least $491,989at least 5151 of 12
Rybelsusat least $51,706at least 538 of 11
Wegovyat least $27,771at least 2518 of 20
Mounjaroat least $640,745at least 6243 of 24
Zepboundat least $116,397at least 11415 of 21
Liraglutide (generic name listing)at least $26,631at least 5317 of 21
Victozaat least $13,894at least 247 of 8
Trulicityat least $875,830at least 9072 of 18
BydureonSuppressedSuppressed2 of 2
ByettaSuppressedSuppressed3 of 3

By quarter, 2025

Q1 2025at least $556,369at least 57723 of 36
Q2 2025at least $693,409at least 72214 of 34
Q3 2025at least $740,900at least 76114 of 34
Q4 2025at least $254,284at least 25525 of 36

By quarter, 2026 (posted so far)

Q1 2026at least $1,621,808at least 1,5569 of 38

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.